Clinician’s Brief published a case report about a German Shepherd diagnosed with blastomycosis. The article discusses the effective use of MVista® Blastomyces Quantitative Antigen EIA for quick and accurate detection of the fungal pathogen.
Clinician’s Brief published a case report “Blastomycosis in a Dog,” that describes a classic example of blastomycosis in a German Shepherd with a cutaneous lesion and a nodular interstitial pattern on thoracic radiographs. As an ancillary diagnostic to cytology, the MiraVista Blastomyces antigen test for dogs (MVista® Blastomyces Quantitative Antigen EIA) was performed on urine from this canine patient. The article highlights the very limited (but possible) zoonotic transmission of Blastomyces through needlestick injury or contaminated bandage materials or surfaces in the clinic environment.
Identification of Blastomyces yeasts through cytology or histology remains the gold standard for diagnosis of blastomycosis; however, other diagnostics are very useful in cases in which identification is unclear or sample acquisition is not feasible. For this purpose, MiraVista Blastomyces antigen test for dogs (MVista® Blastomyces Quantitative EIA) is highly sensitive and specific, cost effective and rapid. Culture of Blastomyces has a slow turnaround time and is often not recommended due to the risk of zoonotic infection (requiring biosafety level 2 containment facilities). Molecular methods (polymerase chain reaction; PCR) for Blastomyces are available from at least one commercial source; however, no external validation has been performed, nor are there any peer-reviewed studies to show the sensitivity and specificity of this PCR test.
Monitoring of the MVista® Blastomyces antigen test for dogs is also beneficial during antifungal therapy for blastomycosis, as the urine antigen concentration is expected to decline with successful treatment. Urine antigen concentration can also be used as an indicator of relapse following discontinuation of antifungal therapy.